/
Other
Chemotherapy
113
Pipeline Programs↗
116
Active Trials↗
71
Companies Involved↗
Chemotherapy is a highly competitive landscape with 113 programs across 71 companies. The most active players are Guangzhou JOYO Pharma Co., Ltd, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Shanghai Henlius Biotech. 31 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical15
Phase 13
Phase 264
Phase 331
Approved
No programs
Analysis
Modality Breakdown
78%
Small molecule
86 of 110 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 110 classified programs, each share of the total. Modality classified for 100% of 113 pipeline programs.
Analysis
Trial Status
489
clinical trials
Completed173 · 35%
Unknown status123 · 25%
Recruiting69 · 14%
Terminated61 · 12%
Not yet recruiting27 · 6%
Active, not recruiting20 · 4%
Other16 · 3%
Clinical Trials
Trial Activity
489 trials
POST URS Chemotherapy Instillation
Recruiting·—·N/A·NCT06167057·264 enrolled
Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 3·NCT05956639·100 enrolled
Page 1 of 33
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)